Stonehage Fleming Financial Services Holdings Ltd Sells 352,382 Shares of Zoetis Inc. (NYSE:ZTS)

Stonehage Fleming Financial Services Holdings Ltd decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 33.8% in the 4th quarter, HoldingsChannel reports. The firm owned 688,758 shares of the company’s stock after selling 352,382 shares during the quarter. Zoetis accounts for 3.1% of Stonehage Fleming Financial Services Holdings Ltd’s portfolio, making the stock its 16th largest holding. Stonehage Fleming Financial Services Holdings Ltd’s holdings in Zoetis were worth $112,219,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Cherry Creek Investment Advisors Inc. lifted its holdings in shares of Zoetis by 2.0% during the 3rd quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock worth $590,000 after acquiring an additional 58 shares during the period. Grove Bank & Trust lifted its stake in Zoetis by 0.5% during the third quarter. Grove Bank & Trust now owns 11,763 shares of the company’s stock worth $2,298,000 after purchasing an additional 61 shares during the last quarter. Hancock Whitney Corp boosted its holdings in shares of Zoetis by 0.3% in the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock valued at $3,628,000 after purchasing an additional 61 shares in the last quarter. Strategy Asset Managers LLC increased its stake in shares of Zoetis by 3.5% in the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock valued at $356,000 after purchasing an additional 62 shares during the last quarter. Finally, Procyon Advisors LLC increased its stake in shares of Zoetis by 1.4% in the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock valued at $768,000 after purchasing an additional 63 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several recent analyst reports. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Stifel Nicolaus dropped their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Leerink Partners initiated coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. JPMorgan Chase & Co. raised their price objective on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Finally, UBS Group began coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $211.89.

Zoetis Stock Up 1.0 %

Shares of NYSE:ZTS opened at $168.63 on Monday. The business has a fifty day simple moving average of $170.10 and a 200 day simple moving average of $179.70. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53. The firm has a market cap of $76.08 billion, a P/E ratio of 31.70, a P/E/G ratio of 2.57 and a beta of 0.89. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last announced its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. During the same period in the prior year, the business posted $1.36 earnings per share. The firm’s revenue was up 11.6% on a year-over-year basis. Analysts predict that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be issued a dividend of $0.50 per share. This is an increase from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 dividend on an annualized basis and a yield of 1.19%. The ex-dividend date of this dividend is Tuesday, January 21st. Zoetis’s dividend payout ratio (DPR) is presently 37.59%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.